Lukemaviir
Lukemaviir is a medication used to treat chronic hepatitis C infection. It is a direct-acting antiviral (DAA) that works by inhibiting the hepatitis C virus (HCV) NS5A protein, which is essential for viral replication. Lukemaviir is typically used in combination with other DAAs, such as glecaprevir/pibrentasvir or sofosbuvir/velpatasvir, to achieve a sustained virologic response (SVR) in patients with genotype 1 HCV infection.
The most common side effects of lukemaviir include headache, fatigue, and nausea. Serious side effects are rare
Lukemaviir was approved by the U.S. Food and Drug Administration (FDA) in 2014 and has since been